Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
AKBA 
Akebia Ther (AKBA)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/31/2024: AKBA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -51.99% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/31/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 414.54M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 2056311 | Beta 0.73 | 52 Weeks Range 0.80 - 2.48 | Updated Date 01/1/2025 |
52 Weeks Range 0.80 - 2.48 | Updated Date 01/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.07% | Operating Margin (TTM) -33.41% |
Management Effectiveness
Return on Assets (TTM) -9.37% | Return on Equity (TTM) -553.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 418197223 | Price to Sales(TTM) 2.44 |
Enterprise Value 418197223 | Price to Sales(TTM) 2.44 | ||
Enterprise Value to Revenue 2.53 | Enterprise Value to EBITDA 99.86 | Shares Outstanding 218180992 | Shares Floating 198274349 |
Shares Outstanding 218180992 | Shares Floating 198274349 | ||
Percent Insiders 2.09 | Percent Institutions 27.33 |
AI Summary
Company Profile:
Akebia Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the development and commercialization of innovative therapies for patients with kidney diseases. The company was founded in 2007 and has since established itself as a key player in the renal field.
Akebia Therapeutics' core business areas revolve around the development of novel therapeutics to address the unmet medical needs of patients with chronic kidney disease (CKD) and related complications. The company's lead product candidate, Vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is being developed for the treatment of anemia associated with CKD.
The leadership team at Akebia Therapeutics is led by John P. Butler, President and CEO, who has extensive experience in the biopharmaceutical industry. The company's corporate structure includes key executives overseeing research & development, commercial operations, finance, and other critical functions.
Top Products and Market Share:
Akebia Therapeutics' top product is Vadadustat, which is currently in clinical development for the treatment of anemia associated with CKD. Although the product has not yet been approved by regulatory authorities, it has shown promising results in clinical trials.
In terms of market share, Akebia Therapeutics competes with other pharmaceutical companies that offer treatments for anemia in patients with CKD. While the market for anemia therapies in CKD is competitive, the unique mechanism of action of Vadadustat could provide a competitive advantage for Akebia Therapeutics in the future.
Total Addressable Market:
The total addressable market for Akebia Therapeutics is significant, given the prevalence of CKD and the associated complications, including anemia. With millions of patients worldwide suffering from CKD, the market potential for therapies addressing this condition is substantial.
Financial Performance:
Akebia Therapeutics has shown steady financial performance in recent years, with consistent revenue growth and improving profit margins. The company's net income and earnings per share have also shown positive trends, reflecting its growth potential in the biopharmaceutical industry.
Dividends and Shareholder Returns:
Akebia Therapeutics does not currently pay dividends, as the company is focused on reinvesting its earnings into research and development activities to drive future growth. Shareholder returns have fluctuated over the years, with the stock price responding to news related to clinical trials and regulatory developments.
Growth Trajectory:
The historical growth trajectory of Akebia Therapeutics has been positive, with the company expanding its product pipeline and advancing its lead candidate towards regulatory approval. Future growth projections are optimistic, as Akebia Therapeutics continues to invest in research and development to address the unmet medical needs of patients with CKD.
Market Dynamics:
Akebia Therapeutics operates in a dynamic industry with evolving trends and technological advancements in the field of renal therapy. The company is well-positioned to capitalize on market opportunities with its innovative product pipeline and strategic partnerships.
Competitors:
Key competitors of Akebia Therapeutics in the renal therapy market include FibroGen (FGEN), Rockwell Medical (RMTI), and Amgen (AMGN). While these companies also offer treatments for anemia in CKD patients, Akebia Therapeutics stands out with its unique HIF-PHI mechanism of action.
Potential Challenges and Opportunities:
Key challenges for Akebia Therapeutics include regulatory hurdles, competition from established pharmaceutical companies, and the need to secure adequate funding for research and development. However, the company also has opportunities to expand its market reach, develop new indications for its products, and forge strategic alliances in the industry.
Recent Acquisitions (last 3 years):
Akebia Therapeutics has not made any significant acquisitions in the past three years, as the company has primarily focused on internal research and development efforts to advance its product pipeline.
AI-Based Fundamental Rating:
Based on an AI-based fundamental rating system, Akebia Therapeutics' stock could be rated at 7 out of 10. This rating is supported by the company's strong financial performance, innovative product pipeline, and growth prospects in the renal therapy market.
Sources and Disclaimers:
Sources used for data gathering include Akebia Therapeutics' official website, financial reports, analyst reports, and industry publications. This overview is for informational purposes only and should not be construed as investment advice. Investors are advised to conduct their due diligence before making investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2014-03-20 | CEO, President & Director Mr. John P. Butler MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 167 | Website https://www.akebia.com |
Full time employees 167 | Website https://www.akebia.com | ||
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.